Innate Immune Functions of Immature Neutrophils

NCT ID: NCT01155674

Last Updated: 2010-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polymorphonuclear neutrophils, or granulocytes, are essential effector cells of the innate immune system against bacterial infections. Their role in sepsis has been long established as the primary phagocyte to clear the infectious process. In the early phase of sepsis, one observes a massive recruitment of immature neutrophils from the bone marrow into peripheral blood, the so-called "band forms" or "left shift cells". Despite the daily clinical use of neutrophil band forms count in the care of septic patients and their abundance in septic blood, no information exists on the fate of these cells, nor on their capacity to mount an efficient innate immune response. It is the goal of this proposal to study the fate and the innate immune functions of immature neutrophils obtained in patients with early septic shock. Immature neutrophils will be separated from mature neutrophils. The following functions will be studied ex vivo in mature vs. immature neutrophils from a series of patients with severe sepsis and septic shock: (1) surface expression of receptors of the innate immunity; (2) production of inflammatory mediators and reactive oxygen species in response to bacterial agonists; (3) chemotaxis; (4) phagocytosis of Gram-positive and Gram-negative bacteria; and (5) ex vivo viability (life span) and resistance to apoptosis. Importantly, the investigators have developed and mastered all in vitro assays and cell separation techniques necessary to address and answer these important questions. This project will undoubtedly shed light on the fate and function of a prominent leukocyte population circulating in patients with severe bacterial infections and sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives

1. Primary objective: To determine the innate immune functions of immature neutrophils in comparison to those from mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case)
2. Secondary objectives: To determine the fate and span life of immature neutrophils in comparison to mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case).

Inclusion criteria

* Patients with severe sepsis or septic shock (according to ACCP/FCCM standard definitions) with \> 5% immature neutrophils.
* Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with \> 5% immature neutrophils.
* Healthy donors

Exclusion criteria

* Severe immunosuppression (e.g. HIV with \< 200 CD4/mm3), treatment with glucocorticoids (\> 300 mg hydrocortisone/day) or other immunosuppressive therapy
* Neutropenia (neutrophils \< 0.5 G/l).
* Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.

Endpoints

* Surface expression of receptors of the innate immunity in immature vs. mature neutrophils.
* Production by immature vs. mature neutrophils of inflammatory mediators and reactive oxygen species in response to bacterial agonists.
* Chemotaxis of immature vs. mature neutrophils.
* Phagocytosis of Gram-positive and Gram-negative bacteria by immature vs. mature neutrophils.
* Ex vivo viability and resistance to apoptosis of immature vs. mature neutrophils.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis SIRS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis patients

Patients presenting sepsis

No interventions assigned to this group

SIRS patients

Patients presenting with the systemic inflammatory response syndrome

No interventions assigned to this group

Healthy subjects

Healthy blood donors

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with severe sepsis or septic shock (according to ACCP/FCCM standard definitions) with \> 5% immature neutrophils.
* Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with \> 5% immature neutrophils.
* Healthy donors

Exclusion Criteria

* Severe immunosuppression (e.g. HIV with \< 200 CD4/mm3), treatment with glucocorticoids (\> 300 mg hydrocortisone/day) or other immunosuppressive therapy
* Neutropenia (neutrophils \< 0.5 G/l).
* Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Geneva

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Hospitals of Geneva

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals of Geneva, Intensive Care

Geneva, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Geneviève Drifte, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jerome Pugin, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CER 09-311

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Personalized Immunotherapy in Sepsis
NCT04990232 COMPLETED PHASE2